Posted by Michael Wonder on 04 Feb 2025
Insurer denies access to drugs granted accelerated approval by FDA
3 January 2025 - An insurer’s decision to delay reimbursement of drugs licensed under the FDA’s accelerated approval program has sparked controversy.
Independence Blue Cross’s recently announced policy bars coverage of FDA approved treatments until 18 months after accelerated approval.
